Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Exenatide78 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00318 | 35140289 | Sci Rep | Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway. | 2022 | Details |
| A00459 | 35072848 | Inflammopharmacology | The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules. | 2022 | Details |
| A00653 | 35014145 | Diabetes Obes Metab | Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT). | 2022 | Details |
| A00703 | 34997159 | Sci Rep | Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease. | 2022 | Details |
| A02615 | 34308859 | Nan Fang Yi Ke Da Xue Xue Bao | [Exendin-4 promotes autophagy to relieve lipid deposition in a NAFLD cell model by activating AKT/mTOR signaling pathway]. | 2021 | Details |
| A03013 | 34164242 | Cureus | Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Non-Alcoholic Steatohepatitis: A Clinical Review Article. | 2021 | Details |
| A03163 | 34106786 | Am J Physiol Cell Physiol | Impaired Ca2+ signaling due to hepatic steatosis mediates hepatic insulin resistance in Alström syndrome mice that is reversed by GLP-1 analog treatment. | 2021 | Details |
| A03232 | 34078383 | J Transl Med | Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4. | 2021 | Details |
| A03561 | 33953700 | Front Endocrinol (Lausanne) | Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway. | 2021 | Details |
| A03840 | 33852508 | Eur J Gastroenterol Hepatol | The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases. | 2022 | Details |
| A03861 | 33841337 | Front Endocrinol (Lausanne) | Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis. | 2021 | Details |
| A04513 | 33592427 | Clin Res Hepatol Gastroenterol | Integrated expression profiles of mRNA and miRNA in a gerbil model of fatty liver fibrosis treated with exenatide. | 2021 | Details |
| A04758 | 33513761 | Metabolites | Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. | 2021 | Details |
| A04892 | 33464703 | Diabetes Obes Metab | Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. | 2021 | Details |
| A05156 | 33352183 | Eur J Pharmacol | The effects of glucagon-like peptide-1 receptor agonists on glycemic control and anthropometric profiles among diabetic patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A05535 | 33216087 | Food Funct | Amelioration of non-alcoholic fatty liver disease by sodium butyrate is linked to the modulation of intestinal tight junctions in db/db mice. | 2020 | Details |
| A06320 | 32930541 | Eur J Histochem | β-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet. | 2020 | Details |
| A06401 | 32892547 | Turk J Med Sci | Exenatide improves cardiovascular risk factors in obese patients with type 2 diabetes mellitus: a prospective study | 2021 | Details |
| A06484 | 32862405 | Endocrine | PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide. | 2020 | Details |
| A06633 | 32800550 | Biochem Biophys Res Commun | Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling. | 2020 | Details |
| A07440 | 32496108 | Rev Esp Enferm Dig | The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials. | 2020 | Details |
| A07814 | 32348835 | Life Sci | Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin. | 2020 | Details |
| A08267 | 32180556 | Mol Metab | Role of ATP-binding cassette transporter A1 in suppressing lipid accumulation by glucagon-like peptide-1 agonist in hepatocytes. | 2020 | Details |
| A08872 | 31955491 | Diabetes Metab Res Rev | Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. | 2020 | Details |
| A09343 | 31783920 | Syst Rev | Diabetes drugs for nonalcoholic fatty liver disease: a systematic review. | 2019 | Details |
| A09569 | 31692226 | Diabetes Obes Metab | Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes. | 2019 | Details |
| A09999 | 31530849 | Sci Rep | Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and α1 Antitrypsin. | 2019 | Details |
| A10476 | 31321014 | Ther Adv Chronic Dis | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus. | 2019 | Details |
| A11010 | 31082799 | J Endocrinol | Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. | 2019 | Details |
| A12156 | 30578967 | Biochim Biophys Acta Mol Cell Biol Lipids | Gut peptide and neuroendocrine regulation of hepatic lipid and lipoprotein metabolism in health and disease. | 2018 | Details |
| A13540 | 29924135 | Braz J Med Biol Res | Exenatide ameliorates hepatic steatosis and attenuates fat mass and FTO gene expression through PI3K signaling pathway in nonalcoholic fatty liver disease. | 2018 | Details |
| A13665 | 29849583 | Gastroenterol Res Pract | Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway. | 2018 | Details |
| A14438 | 29406832 | Can J Physiol Pharmacol | Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates nonalcoholic fatty liver disease. | 2018 | Details |
| A15812 | 28696785 | Arch Physiol Biochem | Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model. | 2017 | Details |
| A16554 | 28319060 | Oncogene | The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. | 2017 | Details |
| A18288 | 27239734 | Lab Invest | C/EBP homologous protein modulates liraglutide-mediated attenuation of non-alcoholic steatohepatitis. | 2016 | Details |
| A18741 | 26976710 | Endocrinol Nutr | Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study. | 2016 | Details |
| A18757 | 26968296 | J Pak Med Assoc | Endocrine and metabolic effects of Glucagon like peptide 1 receptor agonists (GLP1RA). | 2016 | Details |
| A18792 | 26937139 | World J Gastroenterol | Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice. | 2016 | Details |
| A19050 | 26803355 | Diabetes Res Clin Pract | Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide. | 2016 | Details |
| A20523 | 25910576 | Acta Biochim Biophys Sin (Shanghai) | Exendin-4 regulates redox homeostasis in rats fed with high-fat diet. | 2015 | Details |
| A21126 | 25526792 | BMJ Open | Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. | 2014 | Details |
| A21519 | 25258410 | Am J Physiol Gastrointest Liver Physiol | Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver. | 2014 | Details |
| A21861 | 24993337 | Int J Mol Med | Exendin‑4, a glucagon‑like peptide‑1 receptor agonist, modulates hepatic fatty acid composition and Δ‑5‑desaturase index in a murine model of non‑alcoholic steatohepatitis. | 2014 | Details |
| A21945 | 24947350 | Diabetes | SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. | 2014 | Details |
| A22099 | 24823873 | Diabetes Metab Res Rev | Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes. | 2014 | Details |
| A22385 | 24627601 | World J Gastroenterol | Exenatide improves hepatic steatosis by enhancing lipid use in adipose tissue in nondiabetic rats. | 2014 | Details |
| A22526 | 24490861 | Br J Pharmacol | Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration. | 2014 | Details |
| A22624 | 24402015 | Arq Bras Endocrinol Metabol | Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. | 2013 | Details |
| A22765 | 24322742 | Hepatobiliary Pancreat Dis Int | Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review. | 2013 | Details |
| A23823 | 23444782 | Pharmazie | Effects of a new sustained-release microsphere formulation of exenatide, DA-3091, on obese and non-alcoholic fatty liver disease mice. | 2013 | Details |
| A24090 | 23236362 | PLoS One | Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. | 2012 | Details |
| A24655 | 25755424 | J Clin Exp Hepatol | Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis. | 2012 | Details |
| A24996 | 22268099 | Am J Physiol Gastrointest Liver Physiol | Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice. | 2012 | Details |
| A25321 | 21957486 | PLoS One | GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy. | 2011 | Details |
| A25323 | 21956711 | Diabetologia | Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial. | 2011 | Details |
| A25499 | 21765869 | Therap Adv Gastroenterol | The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. | 2011 | Details |
| A25528 | 21745271 | Liver Int | Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis. | 2011 | Details |
| A26323 | 20651599 | Eur J Gastroenterol Hepatol | Treatment with omega-3 fatty acids but not exendin-4 improves hepatic steatosis. | 2010 | Details |
| A26709 | 19921118 | Adv Ther | Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status. | 2009 | Details |
| A27482 | 19885351 | J Diabetes Sci Technol | Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. | 2008 | Details |
| A27935 | 16953843 | Liver Int | Incretin mimetics as a novel therapeutic option for hepatic steatosis. | 2006 | Details |
| A28120 | 16374859 | Hepatology | Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice. | 2006 | Details |
| A33056 | 26774017 | Diabetes Metab | Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association. | 2015 | Details |
| A42614 | 34015974 | Expert Rev Clin Pharmacol | Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome. | 2021 | Details |
| A42934 | 33044023 | J Cell Physiol | Exenatide improves random-pattern skin flap survival via TFE3 mediated autophagy augment. | 2020 | Details |
| A43978 | 30253173 | Toxicol Appl Pharmacol | Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation. | 2018 | Details |
| A45494 | 24315013 | Clin Res Hepatol Gastroenterol | Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients. | 2013 | Details |
| A45751 | 22960075 | Am J Pathol | The glucagon-like peptide-1 receptor agonist Exendin 4 has a protective role in ischemic injury of lean and steatotic liver by inhibiting cell death and stimulating lipolysis. | 2012 | Details |
| A45918 | 22093450 | Liver Int | Glucagon like-peptide 1 receptor and the liver. | 2011 | Details |
| A46216 | 20225248 | Hepatology | Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. | 2010 | Details |
| A47896 | 29870275 | Diabetes Technol Ther | The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs. | 2018 | Details |
| A48199 | 19956143 | Am J Gastroenterol | Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis. | 2009 | Details |
| A49021 | 21131943 | Am J Gastroenterol | Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series. | 2010 | Details |
| A50262 | 35450649 | Carbohydr Polym | Responsive oligochitosan nano-vesicles with ursodeoxycholic acid and exenatide for NAFLD synergistic therapy via SIRT1. | 2022 | Details |
| A52289 | 29074588 | Arterioscler Thromb Vasc Biol | GLP-1 Elicits an Intrinsic Gut-Liver Metabolic Signal to Ameliorate Diet-Induced VLDL Overproduction and Insulin Resistance. | 2017 | Details |
| A52477 | 26546347 | J Cardiovasc Magn Reson | Time course of cardiometabolic alterations in a high fat high sucrose diet mice model and improvement after GLP-1 analog treatment using multimodal cardiovascular magnetic resonance. | 2015 | Details |
| A52501 | 26287659 | Int J Dev Neurosci | Short term exendin-4 treatment reduces markers of metabolic disorders in female offspring of obese rat dams. | 2015 | Details |